文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

还原型谷胱甘肽对重症患者万古霉素肾毒性的保护作用

[Protective effects of reduced glutathione on renal toxicity induced by vancomycin in critically ill patients].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2020-01-01
一句话结论重症患者使用万古霉素后肾功能显著恶化,联用还原型谷胱甘肽可改善肾功能指标并缩短ICU住院时间。

该研究回顾性收集上海交通大学医学院附属瑞金医院ICU 2012年1月至2019年10月使用万古霉素或联用还原型谷胱甘肽(GSH)的重症感染患者临床数据,共纳入217例,仅万古霉素组127例,联用GSH组90例。联用GSH组基线APACHE II评分更低、qSOFA评分更高、基础肾功能更差、万古霉素日均剂量更低。仅万古霉素组用药后SCr和BUN较用药前显著升高;联用GSH组用药后SCr较治疗前显著降低,BUN差异无统计学意义,且ICU住院时间显著短于仅万古霉素组。结论认为万古霉素所致药物性肾损伤发生率高,GSH可显著减轻肾毒性并缩短住院时间。

要点

  • 仅用万古霉素组用药后肾功能显著恶化:SCr 68.0(50.3,103.4)μmol/L vs 用药前56.0(42.0,71.0)μmol/L,BUN 5.4(3.6,9.6)mmol/L vs 4.7(3.5,8.1)mmol/L,均P<0.05。
  • 联用GSH组用药后SCr较治疗前显著降低:81.0(61.0,129.0)μmol/L vs 102.0(64.7,178.0)μmol/L,P<0.05;BUN 8.4(6.2,17.8)mmol/L vs 11.5(6.7,18.4)mmol/L,P>0.05。
  • 联用GSH组ICU住院时间显著短于仅万古霉素组:29.0(14.0,54.2)天 vs 37.0(25.0,55.0)天,P<0.05。
  • 两组ICU死亡率差异无统计学意义;联用GSH组基线APACHE II评分更低、qSOFA评分更高、基础肾功能更差、万古霉素日均剂量更低(22.22±10.09 vs 25.51±9.56 mg×kg-1×d-1,P<0.05)。
  • 仅万古霉素组以肺部感染为主(63.0%),联用GSH组以重症急性胰腺炎为主(46.7%)。

适用人群与场景

  • 上海交通大学医学院附属瑞金医院ICU 2012年1月至2019年10月收治的接受万古霉素或万古霉素联合GSH治疗的重症感染患者,共217例。
  • 仅万古霉素组127例,万古霉素联合GSH组90例;主要入ICU病因包括肺部感染、脓毒症/脓毒性休克、重症急性胰腺炎等。

处置流程与药物剂量

  • 联用GSH组在万古霉素基础上加用GSH静脉输注;原文未写明GSH的具体剂量、给药频次和疗程。
  • 万古霉素日均剂量:仅万古霉素组25.51±9.56 mg×kg-1×d-1,联用GSH组22.22±10.09 mg×kg-1×d-1,两组差异有统计学意义(P<0.05)。

研究设计与关键结果

  • 研究类型为回顾性临床资料分析,纳入217例重症感染患者,仅万古霉素组127例、万古霉素联合GSH组90例。
  • 仅万古霉素组用药后肾功能较用药前显著恶化:SCr 68.0(50.3,103.4)μmol/L vs 56.0(42.0,71.0)μmol/L,BUN 5.4(3.6,9.6)mmol/L vs 4.7(3.5,8.1)mmol/L,均P<0.05。
  • 联用GSH组用药后SCr较治疗前显著降低:81.0(61.0,129.0)μmol/L vs 102.0(64.7,178.0)μmol/L,P<0.05;BUN 8.4(6.2,17.8)mmol/L vs 11.5(6.7,18.4)mmol/L,P>0.05。
  • 联用GSH组ICU住院时间显著短于仅万古霉素组:29.0(14.0,54.2)天 vs 37.0(25.0,55.0)天,P<0.05;两组ICU死亡率差异无统计学意义。
  • 联用GSH组基线APACHE II评分显著低于仅万古霉素组:15.0(10.5,21.0)vs 27.0(20.0,31.0),P<0.01;qSOFA评分显著高于仅万古霉素组:1.0(0,1.0)vs 0(0,0.2),P<0.01。
  • 联用GSH组基础肾功能较仅万古霉素组差:SCr 102.0(64.7,178.0)μmol/L vs 56.0(42.0,71.0)μmol/L,BUN 11.5(6.7,18.4)mmol/L vs 4.70(3.5,8.1)mmol/L,均P<0.05。
  • 两组性别、体重、万古霉素疗程、慢性肾脏病史和ICU死亡率差异无统计学意义。

证据类型、等级与局限

  • 证据类型:回顾性临床资料分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该研究提示重症患者使用万古霉素后药物性肾损伤发生率高,用药后应监测SCr和BUN变化。
  • 联用GSH组用药后SCr较治疗前降低、ICU住院时间缩短,但两组基线APACHE II评分、qSOFA评分、基础肾功能和万古霉素日均剂量存在显著差异,原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To observe the changes of renal function in critically ill patients after using vancomycin and analyze the renal protective effect of reduced glutathione (GSH) on vancomycin nephrotoxicity.

METHODS: The clinical data of patients with severe infection who were administered with vancomycin or plus infusion of GSH admitted to intensive care unit (ICU) of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from January 2012 to October 2019 were collected during the study period, and the patients were divided into only vancomycin group and vancomycin combined with GSH group. The gender, age, body weight, underlying diseases, clinical diagnosis, severity score, renal function before and after taking the medicine, average daily dose and treatment duration of vancomycin and GSH, length of ICU stay and clinical outcomes were recorded and analyzed.

RESULTS: A total of 217 patients were enrolled, with 127 patients in the only vancomycin group, and 90 in the combination with GSH group. There was no statistically significant difference between the two groups in terms of gender, body weight, duration of vancomycin treatment, history of chronic kidney disease, and ICU mortality. The main causes of 217 patients admitted to the ICU were lung infection, sepsis/septic shock, and severe acute pancreatitis (SAP) and so on. The majority of patients in only vancomycin group had lung infections (63.0%), while the main etiology in combination with GSH group was SAP (46.7%). Compared with the only vancomycin group, the acute physiology and chronic health evaluation II (APACHE II) score in the combination with GSH group significantly decreased [15.0 (10.5, 21.0) vs. 27.0 (20.0, 31.0), P < 0.01], but the quick sequential organ failure assessment (qSOFA) score was significantly higher [1.0 (0, 1.0) vs. 0 (0, 0.2), P < 0.01], the basic renal function was poorer [serum creatinine (SCr, μmol/L): 102.0 (64.7, 178.0) vs. 56.0 (42.0, 71.0), blood urea nitrogen (BUN, mmol/L): 11.5 (6.7, 18.4) vs. 4.70 (3.5, 8.1), both P < 0.05], and the average daily dose of vancomycin was lower (mg×kg-1×d-1: 22.22±10.09 vs. 25.51±9.56, P < 0.05). The renal function of patients was getting worse significantly after vancomycin usage as compared with before [SCr (μmol/L): 68.0 (50.3, 103.4) vs. 56.0 (42.0, 71.0), BUN (mmol/L): 5.4 (3.6, 9.6) vs. 4.7 (3.5, 8.1), both P < 0.05]. However, the renal function indexes of the combination with GSH group were better than those before treatment [SCr (μmol/L): 81.0 (61.0, 129.0) vs. 102.0 (64.7, 178.0), P < 0.05; BUN (mmol/L): 8.4 (6.2, 17.8) vs. 11.5 (6.7, 18.4), P > 0.05], and the length of ICU stay was significantly shorter than that in the only vancomycin group [days: 29.0 (14.0, 54.2) vs. 37.0 (25.0, 55.0), P < 0.05].

CONCLUSIONS: The incidence of drug-induced renal injury caused by vancomycin is high. The GSH can significantly reduce their renal toxicity and shorten the length of hospital stay.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Li J, He J, Mao E, et al. [Protective effects of reduced glutathione on renal toxicity induced by vancomycin in critically ill patients]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32788016. doi:10.3760/cma.j.cn121430-20200429-00326

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。